WO1997003692A1 - A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions - Google Patents

A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Info

Publication number
WO1997003692A1
WO1997003692A1 PCT/DK1996/000293 DK9600293W WO9703692A1 WO 1997003692 A1 WO1997003692 A1 WO 1997003692A1 DK 9600293 W DK9600293 W DK 9600293W WO 9703692 A1 WO9703692 A1 WO 9703692A1
Authority
WO
WIPO (PCT)
Prior art keywords
growth hormone
formulation
zinc
optionally
calcium ions
Prior art date
Application number
PCT/DK1996/000293
Other languages
French (fr)
Inventor
Thorkild Christensen
Per Balschmidt
Hans Holmegaard Soerensen
Ole Hvilsted Olsen
Lars Thim
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to EP96922775A priority Critical patent/EP0839049A1/en
Priority to JP9506179A priority patent/JPH11509212A/en
Priority to AU63534/96A priority patent/AU715997B2/en
Priority to BR9609741A priority patent/BR9609741A/en
Publication of WO1997003692A1 publication Critical patent/WO1997003692A1/en
Priority to MXPA/A/1998/000358A priority patent/MXPA98000358A/en
Priority to NO980155A priority patent/NO980155D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • the present invention relates to a stabilized pharmaceutical formulation comprising growth hormone, to a method of making such formulation, to the use of zinc for stabilizing a for- mulation of growth hormone, and to a method for treating a disorder affectable by growth hormone.
  • the growth hormones from man and from the common domestic animals are proteins of approximately 191 amino acids, syn ⁇ thesized and secreted from the anterior lope of the pitui ⁇ tary gland. Human growth hormone consists of 191 amino acids.
  • Growth hormone is a key hormone involved in the regulation of not only somatic growth, but also in the regulation of metabolism of proteins, carbohydrates and lipids. The major effect of growth hormone is to promote growth.
  • the organ systems affected by growth hormone include the skeleton, connective tissue, muscles, and viscera such as liver, intestine, and kidneys.
  • human growth hormone could only be obtained by extraction from the pituitary glands of human cadavers.
  • the very limited supplies of growth hormone restricted the use thereof to longitudinal growth promotion in childhood and puberty for treatment of dwarfism, even though it has been proposed for inter alia treatment of short stature (due to growth hormone deficiency, normal short stature and Turner syndrome) , growth hormone deficiency in adults, infertility, treatment of burns, wound healing, dystrophy, bone knitting, osteoporosis, diffuse ga ⁇ stric bleeding, and pseudoarthrosis.
  • growth hormone has been proposed for increasing the rate of growth of domestic animals or for decreasing the proportion of fat in animals to be slaughtered for human consumption.
  • compositions of growth hormone tend to be un ⁇ stable.
  • Degradation products such as deamidated or sulfoxy- dated products and dimer or polymer forms are generated - especially in solutions of growth hormone.
  • the predominant degradation reactions of hGH are 1) deamida ⁇ tion by direct hydrolysis or via a cyclic succinimide intermediate to form various amounts of L-asp-hGH, L-iso- asp-hGH, D-asp-hGH, and D-iso-asp-hGH (ref 1-3), and 2) oxidation of the methionine residues in positions 14 and 125 (ref 4-9) .
  • the major degradation product of hGH in lyophilized state as well as in solution is deamidated hGH.
  • Deamidation especially takes place at the Asn in position 149 and to a minor extent in position 152.
  • hGH is also rather easily oxidized in positions 14 and 125.
  • the oxidation of hGH in solution forming sulfoxides is nor ⁇ mally due to the oxygen dissolved in the formulation.
  • the solubility of oxygen in distilled water is about 200 ⁇ M (9) .
  • concentration of hGH in a formulation comprising 4 IU/ml is 1.3 mg/ml corresponding to 60nM hGH, oxygen will, at normal storing conditions, be present in an excess of about 3000 times the stoichiometric amount for oxidation of hGH. It is not feasible to try to solve the problem by degassing of buffers before tapping and packing the formulations.
  • the kinetics of degradation depend on temperature, pH and various additives or adjuvants in the hGH formulation.
  • growth hormone Due to the instability, growth hormone is, at present, lyophilized and stored in the lyophilized form at 4°C until it is reconstituted for use in order to minimize the degradation.
  • the lyophilized pharmaceutical formulations comprising hGH are, at present, reconstituted by the patient and then stored as a solution during the use for a period of up to 14 days at 4°C, during which some degradation will take place.
  • the growth hormone as late as possible before use and to store and ship the formulation in a lyophilized state.
  • the chain from the manufacturer to the pharmacy is apt for handling the formulations at a controlled low temperature of e.g. 4°C which allows for a long shelf life of up to two years.
  • a formulation should be stable with the end user in a lyophilized state for about one month and additionally for one month in a reconstituted state in a pen device for the intended period of use of a cartridge.
  • the shift in pattern of administration of growth hormone to the use of pen devices calls for a stable dissolved formulation comprising growth hormone in order to facilitate the handling to be- performed by the patient.
  • a stable dissolved formulation comprising growth hormone may be produced ready to use in the form of cartridges fitting into the pen device used by the patient who may then avoid the reconstitution of the formulation and, hence, will not have to be in the possession of a lyophilized formulation, a suitable vehicle for reconstitution as well as the necessary skill and sterile equipment for sterile reconstitution of the formulation. For safety reasons it will also be desirable to avoid the reconstitution of a lyophilized formulation just before the use of the formulation.
  • Lyophilization is a time consuming and costly process and is also often a "bottleneck" in the production due to the limited capacity of the freeze drier.
  • animal growth hormone may be stabilized with various stabilizers to give decreased formation of insolubles and preservation of the soluble activity in aqueous environments, such stabilizers including certain polyols, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts.
  • stabilizers including certain polyols, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts.
  • Polyols are selected from the group consisting of non-reducing sugars.
  • amino acids are selected from the group consisting of glycine, sarcosine, lysine or salts thereof, serine, arginine or salts thereof, betaine, N,N, -dimethyl-glycine, aspartic acid or salts thereof, glutamic acid or salts thereof;
  • a polymer of an amino acid having a charged side group at physiological pH may be selected from polylysine, polyaspartic acid, polyglutamic acid, polyarginine, polyhistidine, polyornithine and salts thereof; and choline derivatives are selected from the group consisting of choline chloride, choline dihydrogen citrate, choline bitartrate, choline bicarbonate, tricholine citrate, choline ascorbate, choline borate, choline gluconate, choline phosphate, di (choline)
  • US patent specification No. 4,917,685 discloses a delivery device designed to be implanted comprising growth hormone stabilized using the same stabilizers as mentioned in EP 303746.
  • International Patent Publication No. WO 93/12811 discloses stabilized formulations of growth hormone in the form of a lyophilized powder or an aqueous solution comprising asparagine.
  • International Patent Publication No. WO 93/12812 discloses stabilized formulations of growth hormone in the form of a lyophilized powder or an aqueous solution comprising histi ⁇ dine. In such formulations the deamidation is reduced by 25- 30% as compared to a corresponding formulation of growth hormone comprising phosphate buffer.
  • crystals may be formed crystallizing growth hormone with zinc in the presence of histidine.
  • WO 93/19776 discloses protein formulations comprising growth hormone comprising citrate as buffer substance being more stable than formula ⁇ tions comprising phosphate buffer.
  • the formulations may also comprise amino acids such as glycine and alanine and/or man- nitol or other sugar alcohols and/or glycerol and/or other carbohydrates and optionally a preservative such as benzyl alcohol.
  • WO 94/03198 discloses a stable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative.
  • WO 92/17200 discloses stable growth hormone metal ion formulations in the form of dimers showing stability to denaturation.
  • the formulations may comprise glycine and optionally additionally alanine, glutamine, asparagine, arginine or lysine, such amino acids being particularly advantageous when lyophilizing the formulation to create a sufficient mass to form a stable, dry caked formulation.
  • a formulation of hu ⁇ man growth hormone with zinc and optionally lysine or cal ⁇ cium ions before preparation of the final formulation shows a very high stability against deamidation in aqueous solution and is furthermore readily dissolvable in aqueous solvents when lyophilized.
  • the stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formula ⁇ tion.
  • the pharmaceutical formulations of the invention may be formulated for administration in any suitable way, e.g. by parenteral or oral administration or administration to a mucosal membrane, e.g. nasal administration.
  • the pharmaceutical formulation may be presented in the form of a dose comprised in a vial or cartridge or any other suitable container such as a prefilled syringe or a pen device.
  • the formulation of the invention may be in the form of a lyophilized powder to be reconstituted later using conven ⁇ tional vehicles such as distilled water or water for injec- tion or in the form of a solution comprising growth hormone.
  • Such vehicles may comprise conventional preservatives such as phenol, m-cresol and benzyl alcohol.
  • a preferred embodiment of the invention is in the form of a pharmaceutical formulation of human growth hormone pre ⁇ treated with zinc and optionally lysine or calcium ions and further comprising a carrier in the form of a buffered ague ⁇ ous solution of growth hormone.
  • Such formulation is in a ready-to-use form and may be stored and shipped as an aque- ous solution without any considerable degradation.
  • a buffer to be used in a solution of pre-treated growth hor ⁇ mone may e.g. be histidine, citrate, tartrate or phosphate buffer.
  • the buffer is histidine buffer.
  • the pre-treatment solution is preferably adjusted to a value in the interval from about 2 to about 9, more preferred to pH from 6 to 8, especially to about 7-7.3.
  • the pH in the final formulation of pre-treated growth hormone is preferably adjusted to a value of about 2 to about 9, more preferred to a value of about 6 to about 8, especially to a value of about 6.0 to about 6.8.
  • zinc is preferably added in an amount of up to 2mM, preferably from about 1 to about 4 moles Zn per mol of growth hormone, preferably about 1 to 2 moles Zn per mole growth hormone, most preferred about 1 mol Zn per mol growth hormone.
  • Zinc is preferably added in the form of a physiologically acceptable soluble salt such as the chloride.
  • Calcium ions when present are preferably added in the form of a physiologically acceptable soluble salt such as the chloride.
  • the pharmaceutical formulation of the invention may further ⁇ more comprise salts or sugar alcohols for adjusting the tonicity and optionally an excipient in order to facilitate the processing thereof, e.g. lyophilization and the rapid and complete dissolution of a lyophilized formulation when reconstituting the formulation before use.
  • An excipient may be selected from disaccharides such as lac ⁇ tose, trehalose, and sucrose, sugar alcohols such as sorbitol or mannitol, polysaccharides such as the polymers commercialized as Dextran® products such as Dextran® 40,
  • Dextran® 70 or Dextran® 75, and Ficoll® and polyvalent alcohols such as polyethylene glycol or polyvinyl alcohol or a combination of two or more of these.
  • the invention relates to a method of preparing a pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions wherein the growth hormone is dissolved in a solution comprising zinc and optionally lysine or calcium ions by dissolving zinc chloride in deionized water optio ⁇ nally containing lysine or calcium ions, letting the solution stand for a while, adding the growth hormone and optionally adjusting the pH to from about 2 to about 9.
  • the pH may be adjusted by adding an acid which has no adverse effect on the growth hormone, preferably a physiologically acceptable acid e.g. a mineral acid such as hydrochloric acid, sulphuric acid or nitric acid or an organic acid such as acetic acid.
  • a physiologically acceptable acid e.g. a mineral acid such as hydrochloric acid, sulphuric acid or nitric acid or an organic acid such as acetic acid.
  • a physiologically acceptable acid e.g. a mineral acid such as hydrochloric acid, sulphuric acid or nitric acid or an organic acid such as acetic acid.
  • Still another aspect of the invention relates to the use of zinc and optionally lysine or calcium ions for pre-treatment of growth hormone for the formulation of a stabilized formu ⁇ lation of growth hormone.
  • the invention relates to a method for treating a disorder affectable by growth hormone comprising administering a formulation which comprises a growth hormone pre-treated with zinc and optionally lysine or calcium ions.
  • growth hormone may be growth hormone from any origin such as avian, bovine, equine, human, ovine, porcine, salmon, trout or tuna growth hormone, preferably bovine, human or porcine growth hormone, human growth hormone being most preferred.
  • the growth hormone used in accordance with the invention may be native growth hormone isolated from a natural source, e.g. by extracting pituitary glands in a conventional manner, or a growth hormone produced by recombinant techniques, e.g as described in E.B. Jensen and S. Carlsen in Biotech and Bioeng. 3_6, 1- 11 (1990) .
  • the "growth hormone” may also be a truncated form of growth hormone wherein one or more amino acid residues has (have) been deleted; an analogue thereof wherein one or more amino acid residues in the native molecule has (have) been substituted by another amino acid residue, preferably a natural amino acid residue, as long as the substitution does not have any adverse effect such as antigenicity or reduced action; or a derivative thereof, e.g having an N- or C- terminal extension such as Met-hGH.
  • the preferred growth hormone is hGH.
  • dose of growth hormone refers to that amount that provides therapeutic effect in an administration regimen.
  • the formulations hereof are prepared containing amounts of hGH at least about 0.1 mg/ml, preferably upwards of about 10 mg/ml, preferably from about 1 mg/ml to about 40 mg/ml, more preferably from about 1 mg/ml to about 25 mg/ml, e.g. from 1 mg/ml to about 5 mg/ml, calculated on the ready-to-use formulation.
  • these compositions for use of these compositions in administration to human beings suffering from hypopituitary dwarfism, for example, these formulations contain from about 0.1 mg/ml to about 10 mg/ml, corresponding to the currently contemplated dosage regimen for the intended treatment.
  • the concentration range is not critical to the invention and may be varied by the physician supervising the administration.
  • Lysine to be used in accordance with the present invention is preferably the naturally occurring alpha amino acid.
  • the lysine may be 1 or d lysine or a mixture thereof.
  • high stability is obtained when the formulation is more stable than the conventional formulation comprising phosphate buffer and preferably as stable as a corresponding formulation comprising histidine as stabilizer in which the deamidation of hGH is reduced by approximately 20% as compared with phosphate buffer as disclosed in WO 93/12812.
  • the solvent used in the method of the invention may be water, alcohols such as ethyl, n-propyl or isopropyl, butyl alcohol or mixtures thereof.
  • the solvent may comprise a preservative such as phenol, m-cresol or benzyl alcohol.
  • pre-treated is used in the present context in connection with growth hormone formulations to designate a growth hormone which is treated with zinc and optionally lysine or calcium ions before the addition of or to the further components for preparation of a growth hormone for ⁇ mulation.
  • the hGH formulations were prepared by dissolving 24 mg hGH in 2.5 ml of a) 2 mM CaC12 2 + 0.36 mM ZnCl 2 , pH 7-7.3, b) 2 M lysine + 0.36 mM ZnCl 2 , pH 7-7.3 or c) 0.36 mM ZnCl 2 , pH 7-7.3.
  • the preparations a)-c) were reformulated using a PD10 desalting column (Pharmacia) into 3 ml 6 mM histidine, 0.36 mM ZnCl 2 , 8 mg/ml hGH. Thereafter 3 ml 3% benzyl alcohol were added resulting in a final formulation of 4 mg/ml hGH, 3 mM histidine, 0.18 mM ZnCl 2 , 1.5% benzyl alcohol, (pH adjusted to 6.8 adding HCl/NaOH) .

Abstract

A pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.

Description

TITLE
A STABILIZED PHARMACEUΗCAL FORMULATION COMPRISING A GROWTH HORMONE PRE-TREATEDWITHZINC ANDOPTIONALLYLYSINEORCALCIUMIONS
FIELD OF THE INVENTION
The present invention relates to a stabilized pharmaceutical formulation comprising growth hormone, to a method of making such formulation, to the use of zinc for stabilizing a for- mulation of growth hormone, and to a method for treating a disorder affectable by growth hormone.
BACKGROUND OF THE INVENTION
The growth hormones from man and from the common domestic animals are proteins of approximately 191 amino acids, syn¬ thesized and secreted from the anterior lope of the pitui¬ tary gland. Human growth hormone consists of 191 amino acids.
Growth hormone is a key hormone involved in the regulation of not only somatic growth, but also in the regulation of metabolism of proteins, carbohydrates and lipids. The major effect of growth hormone is to promote growth.
The organ systems affected by growth hormone include the skeleton, connective tissue, muscles, and viscera such as liver, intestine, and kidneys.
Until the development of the recombinant technology and the cloning of the growth hormone gene now giving rise to production of e.g. human growth hormone (hGH) and Met-hGH in industrial scale, human growth hormone could only be obtained by extraction from the pituitary glands of human cadavers. The very limited supplies of growth hormone restricted the use thereof to longitudinal growth promotion in childhood and puberty for treatment of dwarfism, even though it has been proposed for inter alia treatment of short stature (due to growth hormone deficiency, normal short stature and Turner syndrome) , growth hormone deficiency in adults, infertility, treatment of burns, wound healing, dystrophy, bone knitting, osteoporosis, diffuse ga¬ stric bleeding, and pseudoarthrosis.
Furthermore, growth hormone has been proposed for increasing the rate of growth of domestic animals or for decreasing the proportion of fat in animals to be slaughtered for human consumption.
Pharmaceutical formulations of growth hormone tend to be un¬ stable. Degradation products such as deamidated or sulfoxy- dated products and dimer or polymer forms are generated - especially in solutions of growth hormone.
The predominant degradation reactions of hGH are 1) deamida¬ tion by direct hydrolysis or via a cyclic succinimide intermediate to form various amounts of L-asp-hGH, L-iso- asp-hGH, D-asp-hGH, and D-iso-asp-hGH (ref 1-3), and 2) oxidation of the methionine residues in positions 14 and 125 (ref 4-9) . The major degradation product of hGH in lyophilized state as well as in solution is deamidated hGH.
Deamidation especially takes place at the Asn in position 149 and to a minor extent in position 152.
hGH is also rather easily oxidized in positions 14 and 125.
The oxidation of hGH in solution forming sulfoxides is nor¬ mally due to the oxygen dissolved in the formulation. The solubility of oxygen in distilled water is about 200 μM (9) . As the concentration of hGH in a formulation comprising 4 IU/ml is 1.3 mg/ml corresponding to 60nM hGH, oxygen will, at normal storing conditions, be present in an excess of about 3000 times the stoichiometric amount for oxidation of hGH. It is not feasible to try to solve the problem by degassing of buffers before tapping and packing the formulations.
At present, it is not believed that these deamidated forms and oxidized forms of hGH should have toxic or altered biological activity or receptor binding properties, but there is indication to the effect that the conformation stability of the sulfoxides is reduced as compared to native hGH.
For the development of a stable, dissolved formulation com¬ prising hGH it is of importance to know the rate of deamida¬ tion and formation of sulfoxides as well as means to control the reactions.
The kinetics of degradation depend on temperature, pH and various additives or adjuvants in the hGH formulation.
Due to the instability, growth hormone is, at present, lyophilized and stored in the lyophilized form at 4°C until it is reconstituted for use in order to minimize the degradation.
The lyophilized pharmaceutical formulations comprising hGH are, at present, reconstituted by the patient and then stored as a solution during the use for a period of up to 14 days at 4°C, during which some degradation will take place.
Furthermore, the process of reconstitution of the lyophilized growth hormone tends to provide difficulties for the patient.
Thus, it is at present preferred to reconstitute the growth hormone as late as possible before use and to store and ship the formulation in a lyophilized state. The chain from the manufacturer to the pharmacy is apt for handling the formulations at a controlled low temperature of e.g. 4°C which allows for a long shelf life of up to two years.
However, the extended use of pen systems for self-medication and the expanded field of use calls for a formulation which is stable for a sufficient long time with the end user under conditions where "sufficient" cooling is not always avai¬ lable.
Preferably, a formulation should be stable with the end user in a lyophilized state for about one month and additionally for one month in a reconstituted state in a pen device for the intended period of use of a cartridge.
Thus, there is a need for more stable formulations of growth hormone being stable in a lyophilized state at a relative high temperature for a period and additionally for a period of use at a relatively high temperature in solution. Such stabilization is of very great importance when moving the administration of the growth hormone from clinics to the ho¬ mes of the individuals to be treated where optimal storage may not be available as indicated above.
Furthermore, the shift in pattern of administration of growth hormone to the use of pen devices calls for a stable dissolved formulation comprising growth hormone in order to facilitate the handling to be- performed by the patient. A stable dissolved formulation comprising growth hormone may be produced ready to use in the form of cartridges fitting into the pen device used by the patient who may then avoid the reconstitution of the formulation and, hence, will not have to be in the possession of a lyophilized formulation, a suitable vehicle for reconstitution as well as the necessary skill and sterile equipment for sterile reconstitution of the formulation. For safety reasons it will also be desirable to avoid the reconstitution of a lyophilized formulation just before the use of the formulation.
Furthermore, it would also be an advantage to avoid the lyo¬ philization step in the production of growth hormone formulations. Lyophilization is a time consuming and costly process and is also often a "bottleneck" in the production due to the limited capacity of the freeze drier.
Thus, there is a need to reduce the rate of the degradation processes in order to allow for dissolved hGH formulations being stable during shelf life and during the period of use of up to one month.
Prior attempts to stabilize hGH has not fully succeeded in preventing the formation of dimer. The problems associated with dimer formation is e.g noted in Becker, G. ., Biotech- nology and Applied Biochemistry 9, 478 (1987) .
International Patent Publication No. WO 89/09614 and Austra¬ lian patent application No. 30771/89 disclose a stable phar¬ maceutical formulation containing human growth hormone, gly- cine, and mannitol. Such a formulation shows improved stabi¬ lity during normal processing and storage in a lyophilized state as well as in the period of use after the reconstitu¬ tion.
Published European patent application No. 303 746 discloses that animal growth hormone may be stabilized with various stabilizers to give decreased formation of insolubles and preservation of the soluble activity in aqueous environments, such stabilizers including certain polyols, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts. Polyols are selected from the group consisting of non-reducing sugars. sugar alcohols, sugar acids, pentaerythritol, lactose, water-soluble dextrans and Ficoll; amino acids are selected from the group consisting of glycine, sarcosine, lysine or salts thereof, serine, arginine or salts thereof, betaine, N,N, -dimethyl-glycine, aspartic acid or salts thereof, glutamic acid or salts thereof; a polymer of an amino acid having a charged side group at physiological pH may be selected from polylysine, polyaspartic acid, polyglutamic acid, polyarginine, polyhistidine, polyornithine and salts thereof; and choline derivatives are selected from the group consisting of choline chloride, choline dihydrogen citrate, choline bitartrate, choline bicarbonate, tricholine citrate, choline ascorbate, choline borate, choline gluconate, choline phosphate, di (choline) sulphate and dicholine mucate.
US patent specification No. 4,917,685 discloses a delivery device designed to be implanted comprising growth hormone stabilized using the same stabilizers as mentioned in EP 303746.
Published European patent application No. 374,120 discloses a stabilized formulation comprising hGH and a polyol having three hydroxy groups. Glycerol and tris (hydroxymethyl) amino¬ methane are mentioned. Furthermore, the presence of histidine hydrochloride as a buffer together with the polyol is disclosed.
International Patent Publication No. WO 92/00998 discloses that crystals may be formed crystallizing growth hormone with zinc.
International Patent Publication No. WO 93/12811 discloses stabilized formulations of growth hormone in the form of a lyophilized powder or an aqueous solution comprising asparagine. International Patent Publication No. WO 93/12812 discloses stabilized formulations of growth hormone in the form of a lyophilized powder or an aqueous solution comprising histi¬ dine. In such formulations the deamidation is reduced by 25- 30% as compared to a corresponding formulation of growth hormone comprising phosphate buffer. Furthermore, it "is disclosed that crystals may be formed crystallizing growth hormone with zinc in the presence of histidine.
International Patent Publication No. WO 93/19776 discloses protein formulations comprising growth hormone comprising citrate as buffer substance being more stable than formula¬ tions comprising phosphate buffer. The formulations may also comprise amino acids such as glycine and alanine and/or man- nitol or other sugar alcohols and/or glycerol and/or other carbohydrates and optionally a preservative such as benzyl alcohol.
International Patent Publication No. WO 94/03198 discloses a stable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative.
Published European patent application No. 177,478 discloses a prolonged release composition comprising zinc and somatotropin in a continuous phase with a biocompatible oil.
Published European patent application No. 216,485 discloses a sustained-release composition comprising zinc and somatotropin in a vehicle comprising a vegetable oil and an adjuvant, especially beeswax, aluminum monostearate, camauba wax or paraffin.
Published European patent application No. 277,043 discloses recovering somatotropin from an aqueous solution by adding a salt of a transition metal and precipitation of an insoluble complex. International Patent Publication No. WO 93/13792 discloses a delayed release implantable device comprising a somatotropin and zinc and optionally a basic side group containing amino acid solubilizing Zn-somatotropin, arginine, alanine, histidine and glutamic acid being mentioned as examples of amino acids.
International Patent Publication No. WO 92/17200 discloses stable growth hormone metal ion formulations in the form of dimers showing stability to denaturation. The formulations may comprise glycine and optionally additionally alanine, glutamine, asparagine, arginine or lysine, such amino acids being particularly advantageous when lyophilizing the formulation to create a sufficient mass to form a stable, dry caked formulation.
BRIEF DESCRIPTION OF THE INVENTION
It has now surprisingly been found that a formulation of hu¬ man growth hormone with zinc and optionally lysine or cal¬ cium ions before preparation of the final formulation shows a very high stability against deamidation in aqueous solution and is furthermore readily dissolvable in aqueous solvents when lyophilized. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formula¬ tion.
The pharmaceutical formulations of the invention may be formulated for administration in any suitable way, e.g. by parenteral or oral administration or administration to a mucosal membrane, e.g. nasal administration. The pharmaceutical formulation may be presented in the form of a dose comprised in a vial or cartridge or any other suitable container such as a prefilled syringe or a pen device. Thus, the formulation of the invention may be in the form of a lyophilized powder to be reconstituted later using conven¬ tional vehicles such as distilled water or water for injec- tion or in the form of a solution comprising growth hormone. Such vehicles may comprise conventional preservatives such as phenol, m-cresol and benzyl alcohol.
A preferred embodiment of the invention is in the form of a pharmaceutical formulation of human growth hormone pre¬ treated with zinc and optionally lysine or calcium ions and further comprising a carrier in the form of a buffered ague¬ ous solution of growth hormone. Such formulation is in a ready-to-use form and may be stored and shipped as an aque- ous solution without any considerable degradation.
A buffer to be used in a solution of pre-treated growth hor¬ mone may e.g. be histidine, citrate, tartrate or phosphate buffer. Preferably, the buffer is histidine buffer.
The pre-treatment solution is preferably adjusted to a value in the interval from about 2 to about 9, more preferred to pH from 6 to 8, especially to about 7-7.3.
For stability reasons the pH in the final formulation of pre-treated growth hormone is preferably adjusted to a value of about 2 to about 9, more preferred to a value of about 6 to about 8, especially to a value of about 6.0 to about 6.8.
In order to obtain the stabilizing effect of zinc and optionally lysine or calcium ions zinc is preferably added in an amount of up to 2mM, preferably from about 1 to about 4 moles Zn per mol of growth hormone, preferably about 1 to 2 moles Zn per mole growth hormone, most preferred about 1 mol Zn per mol growth hormone. Zinc is preferably added in the form of a physiologically acceptable soluble salt such as the chloride.
Calcium ions when present are preferably added in the form of a physiologically acceptable soluble salt such as the chloride.
The pharmaceutical formulation of the invention may further¬ more comprise salts or sugar alcohols for adjusting the tonicity and optionally an excipient in order to facilitate the processing thereof, e.g. lyophilization and the rapid and complete dissolution of a lyophilized formulation when reconstituting the formulation before use.
An excipient may be selected from disaccharides such as lac¬ tose, trehalose, and sucrose, sugar alcohols such as sorbitol or mannitol, polysaccharides such as the polymers commercialized as Dextran® products such as Dextran® 40,
Dextran® 70 or Dextran® 75, and Ficoll® and polyvalent alcohols such as polyethylene glycol or polyvinyl alcohol or a combination of two or more of these.
In a further aspect the invention relates to a method of preparing a pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions wherein the growth hormone is dissolved in a solution comprising zinc and optionally lysine or calcium ions by dissolving zinc chloride in deionized water optio¬ nally containing lysine or calcium ions, letting the solution stand for a while, adding the growth hormone and optionally adjusting the pH to from about 2 to about 9.
The pH may be adjusted by adding an acid which has no adverse effect on the growth hormone, preferably a physiologically acceptable acid e.g. a mineral acid such as hydrochloric acid, sulphuric acid or nitric acid or an organic acid such as acetic acid. In an embodiment of the method of the invention, is added optionally salts and an excipient, whereafter the solution is filled into a container and lyophilized.
Still another aspect of the invention relates to the use of zinc and optionally lysine or calcium ions for pre-treatment of growth hormone for the formulation of a stabilized formu¬ lation of growth hormone.
In yet another aspect the invention relates to a method for treating a disorder affectable by growth hormone comprising administering a formulation which comprises a growth hormone pre-treated with zinc and optionally lysine or calcium ions.
In the present context "growth hormone" may be growth hormone from any origin such as avian, bovine, equine, human, ovine, porcine, salmon, trout or tuna growth hormone, preferably bovine, human or porcine growth hormone, human growth hormone being most preferred. The growth hormone used in accordance with the invention may be native growth hormone isolated from a natural source, e.g. by extracting pituitary glands in a conventional manner, or a growth hormone produced by recombinant techniques, e.g as described in E.B. Jensen and S. Carlsen in Biotech and Bioeng. 3_6, 1- 11 (1990) . The "growth hormone" may also be a truncated form of growth hormone wherein one or more amino acid residues has (have) been deleted; an analogue thereof wherein one or more amino acid residues in the native molecule has (have) been substituted by another amino acid residue, preferably a natural amino acid residue, as long as the substitution does not have any adverse effect such as antigenicity or reduced action; or a derivative thereof, e.g having an N- or C- terminal extension such as Met-hGH. The preferred growth hormone is hGH. The term "dose" of growth hormone refers to that amount that provides therapeutic effect in an administration regimen. The formulations hereof are prepared containing amounts of hGH at least about 0.1 mg/ml, preferably upwards of about 10 mg/ml, preferably from about 1 mg/ml to about 40 mg/ml, more preferably from about 1 mg/ml to about 25 mg/ml, e.g. from 1 mg/ml to about 5 mg/ml, calculated on the ready-to-use formulation. For use of these compositions in administration to human beings suffering from hypopituitary dwarfism, for example, these formulations contain from about 0.1 mg/ml to about 10 mg/ml, corresponding to the currently contemplated dosage regimen for the intended treatment. The concentration range is not critical to the invention and may be varied by the physician supervising the administration.
Lysine to be used in accordance with the present invention is preferably the naturally occurring alpha amino acid. The lysine may be 1 or d lysine or a mixture thereof.
In the present context "high stability" is obtained when the formulation is more stable than the conventional formulation comprising phosphate buffer and preferably as stable as a corresponding formulation comprising histidine as stabilizer in which the deamidation of hGH is reduced by approximately 20% as compared with phosphate buffer as disclosed in WO 93/12812.
The solvent used in the method of the invention may be water, alcohols such as ethyl, n-propyl or isopropyl, butyl alcohol or mixtures thereof. The solvent may comprise a preservative such as phenol, m-cresol or benzyl alcohol. The term "pre-treated" is used in the present context in connection with growth hormone formulations to designate a growth hormone which is treated with zinc and optionally lysine or calcium ions before the addition of or to the further components for preparation of a growth hormone for¬ mulation.
DETAILED DESCRIPTION OF THE INVENTION
The invention is explained more in detail in the below Exam¬ ples which illustrate the invention. They are not to be con¬ sidered as limiting the scope of the invention being defined by the appended claims.
EXPERIMENTAL PART
EXAMPLE
Reduction of the deamidation.
The rate of deamidation after different pre-treatments was examined at 37°C for hGH formulations containing 4 mg/ml hGH, 0.18 mM ZnCl2, 3 mM histidine, 1.5% benzyl alcohol, pH 6.8 as compared to histidine and phosphate buffer at pH 6.8.
The hGH formulations were prepared by dissolving 24 mg hGH in 2.5 ml of a) 2 mM CaC122 + 0.36 mM ZnCl2, pH 7-7.3, b) 2 M lysine + 0.36 mM ZnCl2, pH 7-7.3 or c) 0.36 mM ZnCl2, pH 7-7.3.
After storage 1 h at 4°C (to allow Zn++ to complex with hGH) the preparations a)-c) were reformulated using a PD10 desalting column (Pharmacia) into 3 ml 6 mM histidine, 0.36 mM ZnCl2, 8 mg/ml hGH. Thereafter 3 ml 3% benzyl alcohol were added resulting in a final formulation of 4 mg/ml hGH, 3 mM histidine, 0.18 mM ZnCl2, 1.5% benzyl alcohol, (pH adjusted to 6.8 adding HCl/NaOH) .
As reference formulations were used a) 4mg/ml hGH, 3 mM histidine, 0.18 mM ZnCl2 1.5% benzyl alcohol, pH 6.8; b) 4mg/ml hGH, 3 mM histidine, 1.5% benzyl alcohol, pH 6.8; and c) 4 mg/ml hGH, 3 mM Na2HP04, 1.5% benzyl alcohol, pH 6.8. The reference formulations were not pre-treated with Zn++.
The hGH formulations stated in the below table were stored at 37°C for 7 days, and analyzed for the content of deamidated hGH by IE-HPLC. The results appear from the below table
Formulation pHstart /pHend Content of Content of deamidated deamidated hGH forms as
(%)# compared with histidi-ne (%)
3 mM histidine, 0.18 mM 6.78/6.84 10.0 84
ZnCl2, 1.5% benzyl alcohol, pH 6.8.
Pre-treated in accor¬ dance with procedure a)
3 mM histidine, 0.18 mM 6.75/6.83 11.3 88
ZnCl2, 1.5% benzyl alcohol, pH 6.8.
Pre-treated in accor¬ dance with procedure b)
3 mM histidine, 0.18 6.79/6.87 11.5 89 mM ZnCl2, 1.5% benzyl alcohol, pH
6.8.
Pre-treated in accordance with procedure c)
3 mM histidine, 0.18 mM 6.84/6.92 12.8 99
ZnCl2, 1.5% benzyl alcohol, pH 6.8.
No pre-treatment.
3 mM histidine, 1.5% 6.84/6.92 12.9 100 benzyl alcohol, pH 6.8
3 mM Na2HP04, 1.5% 6.83/6.86 15.9 123 benzyl alcohol, pH 6.8
#Desamido content corrected by 1% per 0.1 pH unit deviation from 6.8.
From the above table it appears that the deamidation rate of hGH is reduced to 84% relative to the histidine (68% relative to the phosphate formulation) when the hGH solution is treated with Zn++ in the presence of Ca++ or lysine prior to resalting into the final histidine formulation. REFERENCES
1) Y.-C.J. Wang and M.A. Hanson. Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers. J. Parenteral Science and Technology 42 (Suppl.) (1988) 53-525.
2) M.C. Manning, K. Patel, R.T. Borchardt. Stability of Protein Pharmaceuticals. Pharmaceutical Research 6 (11) (1989) 903-918.
3) B.A. Johnson, J.M. Shirokawa, W.S. Hancock, M.W. Spellman, L.J. Basa and D.W. Asward. J.Biol.Chem. 264, 1462-71 (1989) .
4) L.C. Teh et al., J.Biol.Chem., 262, 785-794 (1987) .
5) G.W. Becker et al.. Biotech.Appl.Biochem. , 10, 326- 337 (1988) .
6) R.A. Houghten et al. , Arch.Biochem.Biophys. , 178, 350-355 (1977) .
7) R.M. Riggin et al., Anal.Biochem. , 167, 199-209 (1987) .
8) P. Gellerfors et al., Acta Paediatr.Scand (suppl), 370, 93-100 (1990) .
9) M.J. Kaufman, Pharm.Res., 7 (3) 289-292 (1990) .

Claims

1. A pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions.
2. A pharmaceutical formulation as claimed in claim 1 fur¬ ther comprising a carrier in the form of a buffered aqueous solution of growth hormone pre-treated with zinc and optionally lysine or calcium ions.
3. A pharmaceutical formulation as claimed in claim 1 or 2 wherein the pH is adjusted to a value in the interval from about 2 to about 9.
4. A pharmaceutical formulation as claimed in any of the preceding claims wherein the concentration of zinc is up to about 2 mM.
5. A pharmaceutical formulation as claimed in any of the preceding claims further comprising salts and/or saccharides and/or sugar alcohols.
6. A pharmaceutical formulation as claimed in any of claims 1-5 wherein the growth hormone is hGH.
7. A method of preparing a pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions wherein the growth hormone is dissolved in a solution comprising zinc and optionally lysine or calcium ions by dissolving zinc chloride in deionized water optionally containing lysine or calcium ions, letting the solution stand for a while, adding the growth hormone, optionally adding a preservative, and optionally adjusting the pH to from about 2 to about 9.
8. A method as claimed in claim 7, wherein is added optionally salts and/or sugar alcohols and an excipient, whereafter the solution is filled into a container and lyophilized.
9. Use of zinc and optionally lysine or calcium ions for pre-treatment of growth hormone for the formulation of a stabilized formulation of growth hormone.
10. A method for treating a disorder affectable by growth hormone deficiency, comprising administering the formulation of claim 1.
PCT/DK1996/000293 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions WO1997003692A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP96922775A EP0839049A1 (en) 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions
JP9506179A JPH11509212A (en) 1995-07-14 1996-06-28 Stabilized pharmaceutical preparation containing growth hormone pretreated with zinc and optionally lysine or calcium ions
AU63534/96A AU715997B2 (en) 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions
BR9609741A BR9609741A (en) 1995-07-14 1996-06-28 Pharmaceutical formulation processes for preparing it and treating a disorder that can be affected by deficiency of growth hormone and use of zinc and optionally lysine or calcium ions
MXPA/A/1998/000358A MXPA98000358A (en) 1995-07-14 1998-01-12 Stabilized pharmaceutical formulation comprising a pretracted growth hormone with zincy optionally lysine or ions cal
NO980155A NO980155D0 (en) 1995-07-14 1998-01-13 Stabilized pharmaceutical composition comprising a growth hormone pre-treated with zinc and optionally lysine or potassium ions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US119395P 1995-07-14 1995-07-14
US60/001,193 1995-07-14

Publications (1)

Publication Number Publication Date
WO1997003692A1 true WO1997003692A1 (en) 1997-02-06

Family

ID=21694837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1996/000293 WO1997003692A1 (en) 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Country Status (14)

Country Link
EP (1) EP0839049A1 (en)
JP (1) JPH11509212A (en)
KR (1) KR19990028981A (en)
CN (1) CN1190897A (en)
AU (1) AU715997B2 (en)
BR (1) BR9609741A (en)
CA (1) CA2226523A1 (en)
CZ (1) CZ9498A3 (en)
HU (1) HUP9802287A3 (en)
IL (1) IL122583A0 (en)
NO (1) NO980155D0 (en)
PL (1) PL324379A1 (en)
WO (1) WO1997003692A1 (en)
ZA (1) ZA965368B (en)

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
EP0905143A2 (en) * 1997-09-26 1999-03-31 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc and use
US6569406B2 (en) 2000-08-07 2003-05-27 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US6719992B2 (en) 2000-06-26 2004-04-13 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6719990B2 (en) 2000-02-24 2004-04-13 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
EP1666596A1 (en) 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7173115B2 (en) 2000-01-13 2007-02-06 Genentech, Inc. Stra6 polypeptides
US7235633B2 (en) 2000-03-21 2007-06-26 Genentech, Inc. Cytokine receptors and nucleic acids encoding the same
US7268112B2 (en) 2000-03-24 2007-09-11 Genetech, Inc. Use of insulin for the treatment of cartilaginous disorders
EP1897944A2 (en) 1999-12-23 2008-03-12 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO2008067223A2 (en) 2006-11-29 2008-06-05 Genentech, Inc. Il-17a/f heterodimeric polypeptides and therapeutic uses thereof
EP1944317A2 (en) 2000-09-01 2008-07-16 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1953173A1 (en) 1999-06-15 2008-08-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
US7456251B2 (en) 2006-02-02 2008-11-25 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2014298A2 (en) 2000-08-24 2009-01-14 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2050762A2 (en) 1998-03-10 2009-04-22 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
EP2075334A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and methods of use
EP2075254A1 (en) 2004-03-30 2009-07-01 NsGene A/S Therapeutic use of a growth factor, NsG33
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2093570A1 (en) 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP2110434A1 (en) 2002-02-25 2009-10-21 Genentech, Inc. Type-1 cytokine receptor GLM-R
WO2010027404A2 (en) * 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulation of therapeutic polypeptides suitable for oral administration
EP2163562A2 (en) 2005-06-21 2010-03-17 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
EP2228446A1 (en) 1999-12-01 2010-09-15 Genentech, Inc. Secreted and transmembrane polypeptieds and nucleic acids encoding the same
EP2277908A2 (en) 2003-07-08 2011-01-26 Genentech, Inc. IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
US20110059903A1 (en) * 2009-08-06 2011-03-10 Ironwood Pharmaceuticals, Inc. Formulations Comprising Linaclotide
EP2333069A2 (en) 1998-05-15 2011-06-15 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
EP2336164A1 (en) 2005-12-22 2011-06-22 Genentech, Inc. Recombinant production of heparin binding proteins
EP2335725A1 (en) 2003-04-04 2011-06-22 Genentech, Inc. High concentration antibody and protein formulations
EP2336178A1 (en) 2003-12-11 2011-06-22 Genentech, Inc. Methods and compositions for inhibiting C-Met dimerization and activation
EP2343551A1 (en) 2006-04-10 2011-07-13 Genentech, Inc. Disheveled PDZ modulators
WO2011088318A1 (en) 2010-01-15 2011-07-21 University Of Medicine And Dentistry Of New Jersey Use of vanadium compounds to accelerate bone healing
EP2360248A1 (en) 2005-08-24 2011-08-24 The Rockefeller University Ply-GBS mutant lysins
WO2011119487A2 (en) 2010-03-22 2011-09-29 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
EP2389948A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
WO2011163458A2 (en) 2010-06-24 2011-12-29 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2012041328A1 (en) 2010-10-01 2012-04-05 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012045281A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
EP2446894A2 (en) 2004-10-27 2012-05-02 University Of Denver Adrenocorticotropic hormone analogs and related methods
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US8535912B2 (en) 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
US8802628B2 (en) 2008-08-15 2014-08-12 Ironwood Pharmaceuticals, Inc. Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
WO2014152157A2 (en) 2013-03-15 2014-09-25 Bethisrael Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2015057852A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
WO2015057834A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
WO2015067198A1 (en) 2013-11-07 2015-05-14 Generon (Shanghai) Corporation Ltd. Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
WO2016126153A1 (en) 2015-02-04 2016-08-11 Stichting Vu-Vumc Wound healing formulation
WO2016140910A2 (en) 2015-03-04 2016-09-09 University Of Rochester Compositions and methods of using anti-mullerian hormone for treatment of infertility
EP2049148B1 (en) * 2006-07-06 2016-09-28 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
EP3091029A1 (en) 2011-10-31 2016-11-09 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP3124045A2 (en) 2006-12-20 2017-02-01 Xoma (Us) Llc Treatment of il-1 beta related diseases
RU2610436C2 (en) * 2011-06-02 2017-02-10 Баксалта Инкорпорейтед Compositions of recombinant furine
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
US9796784B2 (en) 2009-10-27 2017-10-24 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2018075807A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
EP3332798A1 (en) 2010-08-31 2018-06-13 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in treating viral hepatitis
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
US10543169B2 (en) 2013-11-07 2020-01-28 Generon (Shanghai) Corporation Ltd. Use of IL-22 dimer in manufacture of a medicament for intravenous administration
US10675325B2 (en) 2010-08-11 2020-06-09 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US10786551B2 (en) 2007-08-06 2020-09-29 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in the treatment of fatty liver disease
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2021030251A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
WO2021081440A2 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2022232321A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
WO2022233989A1 (en) 2021-05-06 2022-11-10 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations

Cited By (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
WO1998027980A3 (en) * 1996-12-20 1998-08-13 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US6399103B1 (en) 1996-12-20 2002-06-04 Takeda Chemical Industries, Inc. Method of producing a sustained-release preparation
EP0905143A3 (en) * 1997-09-26 2000-09-06 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc and use
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
US6429296B2 (en) 1997-09-26 2002-08-06 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc and use
EP0905143A2 (en) * 1997-09-26 1999-03-31 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc and use
EP2050762A2 (en) 1998-03-10 2009-04-22 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
EP2333069A2 (en) 1998-05-15 2011-06-15 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1978029A2 (en) 1999-06-15 2008-10-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP1956030A1 (en) 1999-06-15 2008-08-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP1953173A1 (en) 1999-06-15 2008-08-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP2228446A1 (en) 1999-12-01 2010-09-15 Genentech, Inc. Secreted and transmembrane polypeptieds and nucleic acids encoding the same
EP2258848A1 (en) 1999-12-23 2010-12-08 Genentech, Inc. Il-17 homologous polypeptide and therapeutic uses thereof
EP1897944A2 (en) 1999-12-23 2008-03-12 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP2290081A2 (en) 1999-12-23 2011-03-02 Genentech, Inc. IL-17 homologous polypeptide and therapeutic uses thereof
US7173115B2 (en) 2000-01-13 2007-02-06 Genentech, Inc. Stra6 polypeptides
US7741439B2 (en) 2000-01-13 2010-06-22 Genentech, Inc. Isolated stra6 polypeptides
US7855278B2 (en) 2000-01-13 2010-12-21 Genentech, Inc. Antibodies to Stra6 polypeptides
US7939650B2 (en) 2000-01-13 2011-05-10 Genentech, Inc. Stra6 polypeptides
US7048938B2 (en) 2000-02-24 2006-05-23 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
US6719990B2 (en) 2000-02-24 2004-04-13 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
US7235633B2 (en) 2000-03-21 2007-06-26 Genentech, Inc. Cytokine receptors and nucleic acids encoding the same
US7268112B2 (en) 2000-03-24 2007-09-11 Genetech, Inc. Use of insulin for the treatment of cartilaginous disorders
EP1666596A1 (en) 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2075334A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and methods of use
US7037516B2 (en) 2000-06-26 2006-05-02 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6719992B2 (en) 2000-06-26 2004-04-13 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US7030091B2 (en) 2000-06-30 2006-04-18 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
US6569406B2 (en) 2000-08-07 2003-05-27 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6838075B2 (en) 2000-08-07 2005-01-04 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
EP2014298A2 (en) 2000-08-24 2009-01-14 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A2 (en) 2000-09-01 2008-07-16 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
EP2110434A1 (en) 2002-02-25 2009-10-21 Genentech, Inc. Type-1 cytokine receptor GLM-R
EP2335725A1 (en) 2003-04-04 2011-06-22 Genentech, Inc. High concentration antibody and protein formulations
EP3178492A1 (en) 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
EP2093570A1 (en) 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
EP2784084A1 (en) 2003-07-08 2014-10-01 Genentech, Inc. IL-17 A/F heterologous polypeptides and therapeutics uses thereof
EP3594228A1 (en) 2003-07-08 2020-01-15 Genentech, Inc. Il-17a/f heterologous polypedtides and therapeutic uses thereof
EP2277908A2 (en) 2003-07-08 2011-01-26 Genentech, Inc. IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
EP2336178A1 (en) 2003-12-11 2011-06-22 Genentech, Inc. Methods and compositions for inhibiting C-Met dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
EP2289911A2 (en) 2004-03-30 2011-03-02 NsGene A/S Therapeutic use of a growth factor, NsG33
EP2075254A1 (en) 2004-03-30 2009-07-01 NsGene A/S Therapeutic use of a growth factor, NsG33
EP2446894A2 (en) 2004-10-27 2012-05-02 University Of Denver Adrenocorticotropic hormone analogs and related methods
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
EP3056511A2 (en) 2005-06-21 2016-08-17 Xoma (Us) Llc Il-1beta binding antibodies and fragments thereof
EP2314623A1 (en) 2005-06-21 2011-04-27 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
EP2163562A2 (en) 2005-06-21 2010-03-17 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US8105585B2 (en) 2005-08-24 2012-01-31 The Rockefeller Universtiy Ply-GBS mutant lysins
EP2360248A1 (en) 2005-08-24 2011-08-24 The Rockefeller University Ply-GBS mutant lysins
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2336164A1 (en) 2005-12-22 2011-06-22 Genentech, Inc. Recombinant production of heparin binding proteins
US7456251B2 (en) 2006-02-02 2008-11-25 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
US8034899B2 (en) 2006-02-02 2011-10-11 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2389946A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389948A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389947A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389951A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389950A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389949A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2343551A1 (en) 2006-04-10 2011-07-13 Genentech, Inc. Disheveled PDZ modulators
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2049148B1 (en) * 2006-07-06 2016-09-28 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
EP3181147A1 (en) 2006-11-29 2017-06-21 Genentech, Inc. Il-17a/f heterodimeric polypeptides and therapeutic thereof
WO2008067223A2 (en) 2006-11-29 2008-06-05 Genentech, Inc. Il-17a/f heterodimeric polypeptides and therapeutic uses thereof
EP2450050A1 (en) 2006-11-29 2012-05-09 Genentech, Inc. IL-17A/F heterodimeric polypeptides and therapeutic uses thereof
EP3124045A2 (en) 2006-12-20 2017-02-01 Xoma (Us) Llc Treatment of il-1 beta related diseases
US10786551B2 (en) 2007-08-06 2020-09-29 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in the treatment of fatty liver disease
EP2851373A1 (en) 2007-12-20 2015-03-25 Xoma (Us) Llc Methods for the treatment of gout
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
US8802628B2 (en) 2008-08-15 2014-08-12 Ironwood Pharmaceuticals, Inc. Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
WO2010027404A2 (en) * 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulation of therapeutic polypeptides suitable for oral administration
WO2010027404A3 (en) * 2008-09-04 2010-07-01 Ironwood Pharmaceuticals, Inc. Stable formulation comprising therapeutic polypeptides for oral administration
US20110059903A1 (en) * 2009-08-06 2011-03-10 Ironwood Pharmaceuticals, Inc. Formulations Comprising Linaclotide
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US8535912B2 (en) 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
US9796784B2 (en) 2009-10-27 2017-10-24 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
WO2011088318A1 (en) 2010-01-15 2011-07-21 University Of Medicine And Dentistry Of New Jersey Use of vanadium compounds to accelerate bone healing
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9662395B2 (en) 2010-03-22 2017-05-30 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
EP3513810A1 (en) 2010-03-22 2019-07-24 F. Hoffmann-La Roche AG Compositions and methods useful for stabilizing protein- containing formulations
WO2011119487A2 (en) 2010-03-22 2011-09-29 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
EP3586826A1 (en) 2010-06-24 2020-01-01 F. Hoffmann-La Roche AG Compositions and methods for stabilizing protein-containing formulations
EP4008313A1 (en) 2010-06-24 2022-06-08 F. Hoffmann-La Roche AG Compositions and methods for stablizing protein-containing formulations
WO2011163458A2 (en) 2010-06-24 2011-12-29 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
US10702576B2 (en) 2010-08-11 2020-07-07 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US10675325B2 (en) 2010-08-11 2020-06-09 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
EP3332798A1 (en) 2010-08-31 2018-06-13 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in treating viral hepatitis
WO2012041328A1 (en) 2010-10-01 2012-04-05 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012045281A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
RU2610436C2 (en) * 2011-06-02 2017-02-10 Баксалта Инкорпорейтед Compositions of recombinant furine
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
EP3091029A1 (en) 2011-10-31 2016-11-09 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
EP4218937A2 (en) 2011-10-31 2023-08-02 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
WO2014152157A2 (en) 2013-03-15 2014-09-25 Bethisrael Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10391155B2 (en) 2013-10-15 2019-08-27 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
WO2015057852A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
WO2015057834A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
US10543169B2 (en) 2013-11-07 2020-01-28 Generon (Shanghai) Corporation Ltd. Use of IL-22 dimer in manufacture of a medicament for intravenous administration
US11654104B2 (en) 2013-11-07 2023-05-23 Evive Biotechnology (Shanghai) Ltd Use of IL-22 dimer in manufacture of a medicament for intravenous administration
WO2015067198A1 (en) 2013-11-07 2015-05-14 Generon (Shanghai) Corporation Ltd. Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2016126153A1 (en) 2015-02-04 2016-08-11 Stichting Vu-Vumc Wound healing formulation
WO2016140910A2 (en) 2015-03-04 2016-09-09 University Of Rochester Compositions and methods of using anti-mullerian hormone for treatment of infertility
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
US11174306B2 (en) 2016-10-19 2021-11-16 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2018075807A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2021030251A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
WO2021081440A2 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
WO2022232321A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
WO2022233989A1 (en) 2021-05-06 2022-11-10 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain

Also Published As

Publication number Publication date
HUP9802287A2 (en) 1999-02-01
CA2226523A1 (en) 1997-02-06
IL122583A0 (en) 1998-06-15
NO980155L (en) 1998-01-13
EP0839049A1 (en) 1998-05-06
CN1190897A (en) 1998-08-19
KR19990028981A (en) 1999-04-15
HUP9802287A3 (en) 2000-10-30
AU6353496A (en) 1997-02-18
PL324379A1 (en) 1998-05-25
AU715997B2 (en) 2000-02-17
ZA965368B (en) 1997-01-14
MX9800358A (en) 1998-07-31
NO980155D0 (en) 1998-01-13
JPH11509212A (en) 1999-08-17
BR9609741A (en) 1999-03-16
CZ9498A3 (en) 1998-06-17

Similar Documents

Publication Publication Date Title
AU715997B2 (en) A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions
US5851992A (en) Treatment of growth hormone deficiency
US5705482A (en) Pharmaceutical formulation
US20020077461A1 (en) Pharmaceutical formulation
US5654278A (en) Composition and method comprising growth hormone and leucine
US8841252B2 (en) Pharmaceutical formulation
AU699345B2 (en) A pharmaceutical formulation comprising a growth hormone and isoleucine
AU699346B2 (en) A pharmaceutical formulation comprising a growth hormone and valine
AU699369B2 (en) A pharmaceutical formulation comprising a growth hormone and leucine
US6022858A (en) Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5552385A (en) Pharmaceutical formulation
AU4329596A (en) A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
EP0837690A1 (en) A stabilized pharmaceutical formulation comprising a growth hormone and a peptide comprising at least one basic amino acid residue and at least one acid amino acid residue
AU4329496A (en) A stabilized pharmaceutical formulation comprising a growth hormone and lys-x
MXPA98000358A (en) Stabilized pharmaceutical formulation comprising a pretracted growth hormone with zincy optionally lysine or ions cal
MXPA98000309A (en) Stabilized pharmaceutical formulation comprising a hormone of growth and a peptide that comprises at least one residue of basic amino acid and at least one waste of aminoacido ac

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96195537.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996922775

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2226523

Country of ref document: CA

Ref document number: 2226523

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 506179

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/000358

Country of ref document: MX

Ref document number: PV1998-94

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019980700283

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996922775

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-94

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980700283

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996922775

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-94

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019980700283

Country of ref document: KR